122 related articles for article (PubMed ID: 24618433)
21. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ibrahim M; Yadav S; Ogunleye F; Zakalik D
BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
[TBL] [Abstract][Full Text] [Related]
22. Relating pancreatic ductal adenocarcinoma tumor samples and cell lines using gene expression data in translational research.
Shuaichen L; Guangyi W
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):157-162. PubMed ID: 29729710
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Beger C; Ramadani M; Meyer S; Leder G; Krüger M; Welte K; Gansauge F; Beger HG
Clin Cancer Res; 2004 Jun; 10(11):3780-7. PubMed ID: 15173085
[TBL] [Abstract][Full Text] [Related]
24. Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers.
Laitman Y; Keinan Boker L; Liphsitz I; Weissglas-Volkov D; Litz-Philipsborn S; Schayek H; Friedman E
Breast Cancer Res Treat; 2015 Apr; 150(3):631-5. PubMed ID: 25788227
[TBL] [Abstract][Full Text] [Related]
25. MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues.
Seux M; Iovanna J; Dagorn JC; Dusetti NJ
Pancreatology; 2009; 9(1-2):66-72. PubMed ID: 19077456
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
27. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
28. Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor.
Goehringer C; Sutter C; Kloor M; Gebert J; Slater EP; Keller M; Treiber I; Ganschow P; Kadmon M; Moog U
Fam Cancer; 2017 Apr; 16(2):303-309. PubMed ID: 27838800
[TBL] [Abstract][Full Text] [Related]
29. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
30. BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group.
Cho JH; Bang S; Park SW; Chung JB; Song SY
Pancreas; 2008 May; 36(4):337-40. PubMed ID: 18437078
[TBL] [Abstract][Full Text] [Related]
31. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
32. BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping.
Sharma MB; Carus A; Sunde L; Hamilton-Dutoit S; Ladekarl M
Acta Oncol; 2016; 55(3):377-81. PubMed ID: 26004055
[No Abstract] [Full Text] [Related]
33. Familial pancreatic cancer: Concept, management and issues.
Matsubayashi H; Takaori K; Morizane C; Maguchi H; Mizuma M; Takahashi H; Wada K; Hosoi H; Yachida S; Suzuki M; Usui R; Furukawa T; Furuse J; Sato T; Ueno M; Kiyozumi Y; Hijioka S; Mizuno N; Terashima T; Mizumoto M; Kodama Y; Torishima M; Kawaguchi T; Ashida R; Kitano M; Hanada K; Furukawa M; Kawabe K; Majima Y; Shimosegawa T
World J Gastroenterol; 2017 Feb; 23(6):935-948. PubMed ID: 28246467
[TBL] [Abstract][Full Text] [Related]
34. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
35. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
Singh P; Srinivasan R; Wig JD
Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
[TBL] [Abstract][Full Text] [Related]
36. First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.
Meynard G; Mansi L; Lebahar P; Villanueva C; Klajer E; Calcagno F; Vivalta A; Chaix M; Collonge-Rame MA; Populaire C; Algros MP; Colpart P; Neidich J; Pivot X; Curtit E
Oncol Rep; 2017 Mar; 37(3):1573-1578. PubMed ID: 28184945
[TBL] [Abstract][Full Text] [Related]
37. The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.
Martinez-Useros J; Garcia-Foncillas J
Biomed Res Int; 2016; 2016():1869304. PubMed ID: 28078281
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
El Saghir NS; Zgheib NK; Assi HA; Khoury KE; Bidet Y; Jaber SM; Charara RN; Farhat RA; Kreidieh FY; Decousus S; Romero P; Nemer GM; Salem Z; Shamseddine A; Tfayli A; Abbas J; Jamali F; Seoud M; Armstrong DK; Bignon YJ; Uhrhammer N
Oncologist; 2015 Apr; 20(4):357-64. PubMed ID: 25777348
[TBL] [Abstract][Full Text] [Related]
39. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P
Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043
[TBL] [Abstract][Full Text] [Related]
40. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
